On Friday, in the course of current trade, Shares of Zogenix, Inc. (NASDAQ:ZGNX), surged 14.77%, and is now trading at $1.71.
Zogenix, declared new data demonstrating sustained efficacy and tolerability for patients treated with low-dose fenfluramine as an adjunctive therapy for Dravet syndrome. The data was authored by world-renown experts in the field of Dravet syndrome, Berten Ceulemans, M.D., Ph.D. and Lieven Lagae, M.D., Ph.D., from the Universities of Antwerp and Leuven in Belgium, and was presented at the European Paediatric Neurology Society meeting taking place this week in Vienna, Austria. Zogenix intends to initiate Phase 3 clinical studies for ZX008, the Company’s investigational proprietary pediatric formulation of low-dose fenfluramine, during the second half of 2015. ZX008 is designated as an orphan drug in both the U.S. and Europe for the treatment of Dravet syndrome.
Patients with Dravet syndrome experience frequent, severe and potentially life-threatening seizures that typically start in the first year of life. These seizures do not respond to standard anti-epileptic medications and current treatment options are very limited.
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its marketed product comprises Zohydro ER, an extended-release formulation of hydrocodone for the treatment of severe chronic pain.
During an Afternoon trade, Shares of Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), gained 5.59%, and is now trading at $0.940.
Oculus Innovative Sciences, declared that the financial results for its fiscal fourth quarter 2015, ended March 31, 2015, will be released after the U.S. markets close on June 11, 2015. The earnings release will be followed by a conference call at 1:30 p.m. PDT on June 11, 2015, to talk about fiscal fourth quarter and year end results.
Oculus Innovative Sciences, Inc. designs, produces, and markets prescription and non-prescription products based on its Microcyn platform technology for the dermatology, surgical, advanced wound and tissue care, and animal healthcare markets in the United States, Mexico, Europe, and internationally.
Shares of Sysco Corporation (NYSE:SYY), during its Friday’s current trading session fell -0.19%, and is now trading at $37.18.
Sysco Corporation, webcasted its presentation from the 2015 Citi Global Consumer Conference in New York, NY., on Thursday, May 28.
Sysco Corporation, through its auxiliaries, markets and distributes a range of food and related products primarily to the foodservice or food-away-from-home industry. It operates in Broadline and SYGMA segments.
Finally, Newell Rubbermaid Inc. (NYSE:NWL), lost -0.83% Friday.
Newell Rubbermaid, declared the declaration of a quarterly cash dividend of $0.19 per share. The dividend is payable June 15, 2015 to common stockholders of record at the close of business on May 29, 2015.
Newell Rubbermaid Inc. manufactures and markets consumer and commercial products worldwide. It operates through five segments: Writing, Home Solutions, Tools, Commercial Products, and Baby & Parenting.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
